Eli Lilly's breast cancer drug Verzenios is recommended by NICE

CompilationTom Lee

A few days ago, the draft NICE guidelines have recommended Eli Lilly's oral Verzenios (abemaciclib) twice a day for the treatment of hormone receptor-positive, HER2-negative breast cancer in adult patients with breast cancer that has spread to other parts of the body

In February of this year, the British cost-effectiveness regulator rejected Verzenios' application on the grounds that there was no direct evidence to prove the efficacy of this therapy compared with exemestane combined with everolimus.

NICE said in a new statement that the newly released positive recommendations for Verzenios were made after Eli Lilly improved the patient access program and provided further economic modeling data

Verzenios is a CDK4/6 inhibitor that can selectively inhibit cyclin-dependent kinase 4/6 (CDK4/6), restore cell cycle control, and block tumor cell proliferation

In this regard, Meindert Boysen, director of the NICE Health and Technology Assessment Center, said that advanced breast cancer is an incurable disease, and the purpose of treatment is to delay the deterioration of the disease and prolong survival

In June last year, Eli Lilly announced the positive results of the Phase III monarchE study of the targeted anticancer drug Verzenio (abemaciclib) for the treatment of breast cancer

Reference source: NICE recommends Eli Lilly's breast cancer drug Verzenios